Trial Search Results

A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis

A 12 week trial of Adalimumab in subjects with active erosive inflammatory OA who have ahd an inadequate response to NSAID therapy

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Adalimumab


Phase 2


Inclusion Criteria:

   - Age 45 or older, >/=2 tender and 2 swollen joints, inadequate response to NSAID
   therapy, hand radiographs with evidence of erosive changes, acceptable form of birth

Exclusion Criteria:

   - Autoimmune arthropathy, History of psoriasis, Previous TNF therapy, current use of any
   DMARD, evidence of TB, history of Hep C, B, or HIV

Ages Eligible for Study

45 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305